biologics

Market Access
pharmaceutical supply chain

US frets over pharma supply chain security

The pandemic highlighted how fragile the global manufacturing network is, as supply of certain products was limited and regulatory inspections became difficult to carry out.

R&D
3d illustration of molecule model. Science background with molecules and atoms

Investing in biologics excellence

In little over three decades, advances in biotechnology have noticeably disrupted the development landscape of small molecule drugs.